In 2023, Mark Cuban Cost Plus Drug Co. began selling two generic medications cheaper than their branded versions by more than $10,000. 

The FDA sent warning letters Sept. 12 to CVS, Walgreens and six other companies for illegally marketing unapproved eye drug products. 

Cisplatin, a drug used for multiple types of cancer that's been in a severe shortage for months, is close to returning to 100 percent of pre-shortage supply levels, the White House said Sept. 12. 

Shields Health Solutions, a specialty pharmacy solutions company, has secured new partnerships with six systems in 2023, adding to its portfolio of about 850 hospitals. 

A 16-person FDA advisory panel agreed Sept. 12 that oral phenylephrine, an ingredient commonly found in over-the-counter cold and allergy medications, does not help with nasal congestion. 

Jazz Pharmaceuticals is the latest drugmaker to impose pricing restrictions for 340B participants, according to a Sept. 11 news release from the 340B Health organization. Its decision makes it the 25th drugmaker to impose the restrictions since 2020. 

 FDA advisory members are meeting Sept. 11-12 to vote on whether phenylephrine should be reclassified as ineffective amid data suggesting the common ingredient in over-the-counter cold medicines does not relieve symptoms when taken orally. 

Novartis pulled one drug lot from the market after finding crystal formation in some bottles, which could lead to incorrect dosing, the FDA said Sept. 11. 

On Sept. 12, the CDC director delivered the final stamp of approval to XBB.1.5-focused COVID-19 boosters, which could be available to the public later this week.

In July, the European Medicines Agency began reviewing GLP-1 receptor agonists, including Ozempic, Saxenda and Wegovy, because of Icelandic patients reporting thoughts of suicide and self-harm. The U.S. has not launched a similar probe.